CCK-2/gastrin receptor-targeted tumor imaging with 99mTc-labeled minigastrin analogs

Journal of Nuclear Medicine

Volumn 46, Issue 10, 2005, Pages 1727-1736

  Nock, Berthold A ^a   Maina, Theodosia ^a   Béhé, Martin ^b   Nikolopoulou, Anastasia ^a   Gotthardt, Martin ^b   Schmitt, Jörg S ^c   Behr, Thomas M ^b   Mäcke, Helmut R ^c  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

99mTc labeled minigastrin; Cholecystokinin 2 gastrin receptor; Tetraamine peptides; Tumor targeting

Indexed keywords

AMINE; CHOLECYSTOKININ B RECEPTOR; DEMOGASTRIN 1 TC 99M; DEMOGASTRIN 2 TC 99M; DEMOGASTRIN 3 TC 99M; GASTRIN DERIVATIVE; GASTRIN RECEPTOR; MINIGASTRIN TC 99M; TETRAAMINE DERIVATIVE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GASTRIN; MINIGASTRIN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ACINAR CELL; ADULT; ALKALINITY; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CASE REPORT; CELL MEMBRANE; CONJUGATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HUMAN; HYDROPHILICITY; IMAGING SYSTEM; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THYROID MEDULLARY CARCINOMA; TISSUE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DRUG DELIVERY SYSTEM; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; SCINTISCANNING; SYNTHESIS;

ANIMALS; DRUG DELIVERY SYSTEMS; GASTRINS; HUMANS; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33644695474     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Breeman WAP, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2001;28:1421-1429.
2. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabeled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imaging. 2003;30:463-469.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
4. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl 1):67S-75S.
5. Béhé M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399-418.
6. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644-647.
7. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567-573.
8. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413-1417.
9. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377-1386.
10. 2+ mobilization and clonal growth. Cancer Res. 1993;53:5208-5213.
11. Matsumori Y, Katakami N, Ito M, et al. Cholecystokinin-B/gastrin receptor: a novel molecular probe for human small cell lung cancer. Cancer Res. 1995;55:276-279.
12. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
13. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging. 2004;31:803-810.
14. Upp JR, Singh P, Townsend CM, Thompson JC. The clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989;49:488-492.
15. Imdahl A, Mantamadiotis T, Eggstein S, Farthmann EH, Baldwin GS. Expression of gastrin, gastrin/CCK-B and gastrin CCK-C receptors in human colorectal carcinomas. J Cancer Res Clin Oncol. 1995;121:661-666.
16. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin. Eur J Nucl Med. 1998;25:424-430.
17. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481-490.
18. 8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:2081-2087.
19. Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27:1312-1317.
20. Behr TM, Jenner N, Béhé M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029-1044.
21. Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-DGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labeled minigastrin derivatives. Eur J Nucl Med Mol Imaging. 2003; 30:1140-1146.
22. 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med. 2004;45:485-494.
23. Behr TM, Béhé M. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109.
24. 99mTc-Labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235-2268.
25. Aloj L, Panico M, Caracò C, et al. In vitro and in vivo characterization of indium-111 and technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. Cancer Biother Radiopharm. 2004;19:93-98.
26. Laverman P, Béhé M, Oyen WJG, et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjugate Chem. 2004;15:561-568.
27. 1]minigastrin. Bioconjugate Chem. 2004;15:864-871.
28. 3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging. 2002;29:742-753.
29. 99mTc: a preclinical study. J Med Chem. 2005;48:100-110.
30. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging. 2003;30:1211-1219.
31. Mantegazzi D, Ianoz E, Lerch P, Nicolò E, Chapuis G. Preparation and crystal structure of polymeric lithium[dioxoTc(V)-tetraazaundecane]- bis(trifluoromethanesulfonate) complex. Inorg Chim Acta. 1990;176:99-105.
32. +. Inorg Chem. 1988;27:4127-4130.
33. Bläuenstein P, Pfeiffer G, Schubiger PA, et al. Chemical and biological properties of a cationic Tc-tetraamine complex. Int J Appl Radiat Isot. 1985;36:315-317.
34. Prakash S, Went MJ, Blower PJ. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol. 1996;23:543-549.
35. Svoboda M, Dupuche MH, Lambert M, Bui D, Christophe J. Internalization-sequestration and degradation of cholecystokinin (CCK) in tumoral rat pancreatic AR 4-2 J cells. Biochim Biophys Acta. 1990;1055:207-216.
36. Béhé M, Kluge G, Becker W, Gotthardt M, Behr T. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med. 2005;46:1012-1015.